Weaver Marcia R, Conover Christopher J, Proescholdbell Rae Jean, Arno Peter S, Ang Alfonso, Uldall Karina K, Ettner Susan L
Department of Health Services and International Training and Education Center on Health, University of Washington, 901 Boren, Suite 1100, Seattle, WA 98104, USA.
J Ment Health Policy Econ. 2009 Mar;12(1):33-46.
Triply diagnosed patients, who live with HIV and diagnosed mental health and substance abuse disorders, account for at least 13% of all HIV patients. This vulnerable population has substantial gaps in their care, attributable in part to the need for treatment for three illnesses from three types of providers.
The HIV/AIDS Treatment Adherence, Health Outcomes and Cost study (HIV Cost Study) sought to evaluate the cost-effectiveness of integrated HIV primary care, mental health, and substance abuse services among triply diagnosed patients. The analysis was conducted from a health sector budget perspective.
Patients from four sites were randomly assigned to intervention group (n=232) or control group (n=199) that received care-as-usual. Health service costs were measured at baseline and three, six, nine and 12 months and included hospital stays, emergency room visits, outpatient visits, residential treatment, formal long-term care, case management, and both prescribed and over-the-counter medications. Costs for each service were the product of self-reported data on utilization and unit costs based on national data (2002 dollars). Quality of life was measured at baseline and six and 12 months using the SF-6D, as well as the SF-36 physical composite score (PCS) and mental composite score (MCS).
During the 12 months of the trial, total average monthly cost of health services for the intervention group decreased from USD 3235 to USD 3052 and for the control group decreased from USD 3556 to USD 3271, but the decreases were not significant. For both groups, the percentage attributable to hospital care decreased significantly. There were no significant differences in annual cost of health services, SF-6D, PCS or MCS between the intervention and control group.
The results of this randomized controlled trial did not demonstrate that the integrated interventions significantly affected the health service costs or quality of life of triply diagnosed patients. Professionals could pursue coordination or integration of care guided by the evidence that it does not increase the cost of care. The results do not however, provide an imperative to introduce multi-disciplinary care teams, adherence counseling, or personalized nursing services as implemented in this study.
There is not enough evidence to either limit continued exploration of integration of care for triply diagnosed patients or adopt policies to encourage it, such as financial reimbursement, grants regulation or licensing.
Future trials with interventions with lower baseline levels of integration, longer duration and larger sample sizes may show improvement or slow the decline in quality of life. Future researchers should collect comprehensive cost data, because significant decreases in the cost of hospital care did not necessarily lead to significant decreases in the total cost of health services.
同时患有艾滋病病毒(HIV)、精神健康障碍和药物滥用障碍的三重诊断患者,至少占所有HIV患者的13%。这一弱势群体在医疗护理方面存在很大差距,部分原因是需要由三类医疗服务提供者针对三种疾病进行治疗。
HIV/艾滋病治疗依从性、健康结果与成本研究(HIV成本研究)旨在评估针对三重诊断患者的HIV初级医疗、精神健康和药物滥用综合服务的成本效益。该分析是从卫生部门预算的角度进行的。
来自四个地点的患者被随机分配到干预组(n = 232)或接受常规护理的对照组(n = 199)。在基线以及第3、6、9和12个月测量卫生服务成本,包括住院、急诊就诊、门诊就诊、住院治疗、正规长期护理、病例管理以及处方药和非处方药。每项服务的成本是基于国家数据(2002年美元)的自我报告的使用数据与单位成本的乘积。使用SF - 6D以及SF - 36身体综合评分(PCS)和精神综合评分(MCS)在基线以及第6和12个月测量生活质量。
在试验的12个月期间,干预组卫生服务的月平均总成本从3235美元降至3052美元,对照组从3556美元降至3271美元,但降幅不显著。两组中,归因于住院护理的百分比均显著下降。干预组和对照组在卫生服务年度成本、SF - 6D、PCS或MCS方面没有显著差异。
这项随机对照试验的结果并未表明综合干预对三重诊断患者的卫生服务成本或生活质量有显著影响。专业人员可以在不增加护理成本的证据指导下寻求护理的协调或整合。然而,结果并未表明必须引入本研究中实施的多学科护理团队、依从性咨询或个性化护理服务。
没有足够的证据来限制对三重诊断患者护理整合的持续探索,也没有足够的证据来采取鼓励整合的政策,如财务报销、拨款监管或许可。
未来采用整合基线水平较低、持续时间更长且样本量更大的干预措施的试验可能会显示生活质量有所改善或下降速度减缓。未来的研究人员应收集全面的成本数据,因为住院护理成本的显著下降不一定会导致卫生服务总成本的显著下降。